Madrigal Pharmaceuticals, Inc. MDGL
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and related liver conditions. Its lead product, Rezdiffra (resmetirom), is a li…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees915
TickerMDGL
Statistics
Market Cap$11.52B
Revenue (TTM)$958.4M
Net Income-$288.3M
Net Margin-30.1%
EPS$-12.85
P/E-37.43
P/S9.66
P/B20.11
EV/EBITDA-33.34
ROE-49.3%
Dividend Yield—
Price$499.75
Data: Twelve Data · Revenue = mcap / P/S